Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GALT
STRONG SELLGalectin Therapeutics Inc. · Healthcare · United States · $229M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the research and development of therapies for fibrotic liver diseases and cancer. The company's competitive moat is centered on its proprietary galectin-3 inhibitor, belapectin, which is designed to target the root causes of NASH cirrhosis and enhance cancer immunotherapies. It operates as a highly specialized biotechnology player addressing complex, high-value medical indications with significant unmet needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.65 | -0.74 | -0.76 | -0.48 | — | -0.39 | -0.37 | -0.33 | — |
| Shares | 59.4M | 61.9M | 63.2M | 65.2M | +9.7% | 65.9M | — | — | — |
| Debt | 39.9M | 71.8M | 106.2M | 133.8M | 49.7% | 138.7M | — | — | — |
| Equity | -32.2M | -60.2M | -103.1M | -126.2M | — | — | — | — | — |
| Op CF | -31.1M | -33.0M | -41.8M | -23.9M | — | -20.1M | — | — | — |
| Inv CF | 0 | 0 | 0 | 0 | — | — | — | — | — |
| Fin CF | 10.0M | 40.0M | 31.2M | 26.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GALT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GALT | Galectin Therapeutics Inc.(you) | $229M | 9 | STRONG SELL |
| AVXL | Anavex Life Sciences Corp. | $222M | 9 | STRONG SELL |
| TRDA | Entrada Therapeutics, Inc. | $227M | 8 | STRONG SELL |
| LCTX | Lineage Cell Therapeutics, Inc. | $257M | 8 | STRONG SELL |
| TTRX | Turn Therapeutics Inc. | $254M | 8 | STRONG SELL |
| TARA | Protara Therapeutics, Inc. | $226M | 12 | STRONG SELL |
| RNAC | Cartesian Therapeutics, Inc. | $232M | 12 | STRONG SELL |
| NMRA | Neumora Therapeutics, Inc. | $276M | 8 | STRONG SELL |
| GLSI | Greenwich LifeSciences, Inc. | $191M | 8 | STRONG SELL |
| NBP | NovaBridge Biosciences | $205M | 11 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.6%